Amendments to the Claims:

This listing of claims will replace all prior versions and listings of claims in the application.

1 to 16. (canceled)

17. (currently amended) A method of treating cancer comprising co-administration of interleukin 18 and a recombinant herpes simplex virus that selectively replicates in cancer cells, wherein said interleukin 18 is administered as a protein and wherein the γ34.5 gene, the ICP6 gene and the ICP47 gene of the recombinant herpes simplex virus have been deleted or inactivated.

18. (canceled)

19. (currently amended) The method according to claim 17 ~~or 18~~, wherein the interleukin 18 is administered systemically.

20. (previously presented) The method according to claim 19, further comprising local administration of interleukin 12 at a tumor tissue.

21. (previously presented) The method according to claim 19, further comprising local administration at a tumor tissue of a recombinant herpes simplex virus that selectively replicates in cancer cells, wherein a gene coding for interleukin 12 has been inserted expressively in the genomic DNA of the recombinant herpes simplex virus.

22. (currently amended) The method according to claim 17 ~~or 18~~, wherein the recombinant herpes simplex virus is injected into a tumor tissue.

23. (currently amended) The method according to claim 17 ~~22~~, wherein the cancer is located separately from the tumor tissue injected with the herpes simplex virus.

24. (currently amended) A method according to claim 17 or 19 ~~18~~, wherein said interleukin 18 is administered in an amount that is ineffective for interleukin 18 alone to treat cancer ~~the γ34.5 gene and ICP6 gene of the recombinant herpes simplex virus have been deleted or inactivated~~.

25. (currently amended) A method according to claim 17 or 19 ~~24~~, wherein said interleukin 18 is administered at a dose sufficiently low to avoid toxicity ~~the ICP47 gene of the recombinant herpes simplex virus has also been deleted or inactivated~~.

26. (currently amended) A method of treating cancer, comprising administering a recombinant herpes simplex virus that selectively replicates in cancer cells into a tumor tissue and systemically administering interleukin 18 as a protein, wherein the γ34.5 gene ~~and~~, the ICP6 gene and the ICP47 gene of the recombinant herpes simplex virus have been deleted or inactivated, and a gene coding for interleukin 12 has been inserted expressively in the genomic DNA of the recombinant herpes simplex virus.

27. (canceled)

28. (new) A method according to claim 26, wherein said interleukin 18 is administered in an amount that is ineffective for interleukin 18 alone to treat cancer.

29. (new) A method according to claim 26, wherein said interleukin 18 is administered at a dose sufficiently low to avoid toxicity.

30. (new) A method according to claims 17 or 26, wherein interleukin-18 is administered by injection in amount of 0.1 to 1000 μg/kg.